252 Принципы и практика психофармакотерашш

59. Keck РЕ, McElroy SL, Pope HG. Epidemiology of NMS. J Clin Psychiatry 1991; 21:148-151.

60. Mesh H, Molcho A, Aizenberg D, Munitz H. The calcium antagonist nifedipine in recurrent neu-roleptic malignant syndrome. Clin Neuropharma-col 1988; 11:552-555.

61. Sakkas P, Davis JM, Hau J, Wang Z. Pharmacothe-rapy of NMS. Psychiatr Ann 1991; 21:157-164.

62. Addonizio G, Susman VL ЕСТ as a treatment al­ternative for patients with symptoms of neuro-leptic malignant syndrome. J Clin Psychiatry 1987; 48: 102-105.

63. Davis JM, Janicak PG, Sakkas P, Gilmore C, Wang Z. Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convs Ther 1991; 7 (2): 111-120.

64. Janicak PG, Easton MS, Comaty JE, Dowd S, Da-vis JM. Efficacy of ЕСТ in psychotic and nonp-sychotic depression. Convuls Ther 1989; 5 (4): 314-320.

65. Janicak PG, Bresnahan DB, Sharma R, Davis JM, Comaty JE, Malinick C. A comparison of thiothixe-ne with chlorpromazine in the treatment of ma­nia. J Clin Psychopharmacol 1988; 8 (1): 33-37.

66. Janicak PG, Javaid JI, Sharma RP, Comaty JE, Pe-terson J, Davis JM. Trifluoperazine plasma levels and clinical response. J Clin Psychopharmacol 1989; 9 (5): 340-346.

67. Miller DD, Sharafuddin MJA, Kathol RG. A case of clozapine-induced NMS. J Clin Psychiatry 1991; 52:99-101.

68. Anderson ES, Powers PS. NMS associated with clozapine use. J Clin Psychiatry 1991; 52: 102-104.

69. DasGupta K, Young A. Clozapine-induced NMS. J Clin Psychiatry 1991; 52:105-107.

70. Cole JO, Davis JM. Antipsychotic drugs. In: Bel-lak L, ed. The schizophrenic syndrome. NewYork: Grune & Stratton, 1969; 478: 568.

71. Boshes RA, Davis JM. Medical side effects of psy-choactive drugs. In: Berger PA, Brodie HK, eds. American handbook of psychiatry. Vol. 8. New York: Basic Books, 1986.

72. Lieberman J, Kane JM, Johns CA. Clozapine guide­lines for clinical management. J Clin Psychiatry 1989; 58: 329-338.

73. Land W, Salzman C. Risperidone: a novel anti-psychotic medication. Hosp Comm Psychiatry 1994:45:131-134.

74. Zarate CA, Siegel A, Nakamura A, et al. Risperi­done in the elderly. New research #64. Presenta-

tion at the 1996 Annual Meeting of the American Psychiatric Association. NewYork, NY, May 1996.

75. Madhusoodanan S, Brenner R, Araujo L, et al. Ef­ficacy of risperidone treatment for psychoses as-socited with schizophrenia, schizoaffective disor­der, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56: 514-518.

76. Davis JM, Janicak PG, Linden R, Moloney J, Pav-kovic I. Neuroleptics and psychotic disorders. In: Coyle JT, Enna SJ, eds. Neuroleptics: neurochem-ical, behavioral, and clinical perspectives. New York: Raven Press, 1983.

77. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic. A dou­ble blind comparison versus chlorpromazine/ benztropine. Arch Gen Psychiatry 1988; 45: 789.

78. Alvir JMJ, Lieberman JA, Safferman AZ, Schwim-er JL, Schaaf JA. Clozapine-induced agranulocy-tosis: incidence and risk factors in the United States. N EnglJ Med 1993; 329 (3): 162-167.

79. Chengappa KNR, Gopalani A, Haught MK, McChes-ney K, Baker RW, Schooler NR. The treatment of clozapine-associated agranulocytosis with gra-nulocyte colony-stimulating factor (G-CSF). Psy­chopharmacol Bull 1996; 32: 111-121.

80. Kidron R, Averbuch I, Klein E, et al. Carbamaze-pine-induced reduction of blood levels of ha-loperidol in chronic schizophrenia. Biol Psychi­atry 1985; 20: 219-222.

81. Jann MW, Fidone GS, Hernandez JM, et al. Clini­cal implications of increased antipsychotic plas­ma concentrations upon anticonvulsant cessa­tion. Psychiatric Res 1989; 28:153-159.

82. Goff DC, Midha KK, Brotman AW, et al. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991; 148: 790-792.

83. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13(1): 57-67.

84. Perry PJ, Miller D, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-235.

85. Haring C, Barnas C, Saria A, et al. Dose-related plasma levels of clozapine. J Clin Psychopharma­col 1989; 9: 71-72.

86. Cobb CD, Anderson CB, Seidel DR. Possible in­teraction between clozapine and lorazepam [Let­ter]. Am J Psychiatry 1991; 148:1606-1607.